Obulytix

Precision Lysin Therapeutics: a new class of targeted antibiotics for the treatment of hospital-acquired bacterial pneumonia 

Project title: Precision Lysin Therapeutics (PLTs) for polymicrobial Gram-negative HABP/VABP and associated bacteremias 

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are severe infections frequently caused by multidrug-resistant Gram-negative pathogens, resulting in high morbidity and mortality. Lysins, enzymes naturally produced by bacteriophages to kill bacteria, are a promising antibacterial modality, but their application against Gram-negative bacteria has historically been constrained by limited activity under physiological conditions. 

Obulytix is developing PLTs, a novel class of engineered lysins, containing an outer membrane-penetrating peptide and an enzymatic domain that destroys the cell wall. Importantly, PLTs remain active under physiologically relevant conditions and in disease-specific infection models, supporting their development as a new antibacterial modality. 

Using a proprietary platform that combines synthetic biology, high-throughput screening, and machine learning, Obulytix is advancing a pipeline of PLTs against priority multidrug-resistant Gram-negative pathogens associated with severe infections and significant unmet medical need. The PACE award will support the expansion of Obulytix’s pipeline into respiratory infections, complementing its lead program targeting multidrug-resistant Acinetobacter baumannii bloodstream infections. The project will generate translational data on PLT pharmacology, resistance potential and efficacy in preclinical lung infection models, with the goal of advancing up to three candidates toward preclinical development. 

By helping to unlock the therapeutic potential of lysins against Gram-negative pathogens, this program could establish PLTs as a new class of precision antibacterial medicines for severe respiratory infections. Successful development may lead to faster infection control, reduced reliance on last-resort antibiotics, shorter hospital stays, and improved outcomes for patients affected by life-threatening multidrug-resistant bacterial pneumonia. 

Obulytix infographic

Company summary

Obulytix is a Belgian biotechnology company developing next-generation precision antibiotics to combat some of the world’s most dangerous multidrug-resistant bacterial infections. Its pioneering Precision Lysin Therapeutics (PLT) platform combines the specificity of engineered biologics with a novel mechanism of action and a high barrier to resistance, offering a promising new approach against hard-to-treat Gram-negative pathogens. Powered by proprietary AI-driven protein engineering and high-throughput discovery technologies, Obulytix is advancing a pipeline of targeted antibacterial therapies with strong preclinical validation, including efficacy against Acinetobacter baumannii, a critical priority pathogen identified by the World Health Organization.  

Visit website